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Uncontrolled diabetes and health care 





Despite size and relevance of uncontrolled diabetes, robust evidence on its effects on health care 
utilisation is very limited, especially among European countries. We employed longitudinal 
administrative data from Spain (2004-2010) to explore the relationship between uncontrolled type 
2 diabetes and health care utilisation. We used a biomarker (glycated haemoglobin, HbA1c) to 
detect the presence of uncontrolled diabetes and explore its effects on both primary and secondary 
health care. We estimated a range of panel count data models, including negative binomials with 
random effects, dynamic and hurdle specifications to account for unobserved heterogeneity, 
previous utilisation and selection. We found uncontrolled diabetes in between 27-30% of patients 
of both genders. Our estimates suggested that although women appeared to systematically 
consume more health care compared to men, their consumption levels did not seem to be 
influenced by uncontrolled diabetes. Conversely, among men uncontrolled diabetes increased the 
average number of GP visits per year by between 3-3.4%, specialist visits by 5.3-6.1%, depending 
on specifications, and also extended annual hospital length of stay by 15%. We also found some 
evidence of heterogeneity in utilisation based on the level of uncontrolled diabetes among male 
individuals. Overall, our results suggested the need for different diabetes management plans 
depending on gender and levels of glycaemic control. 
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1. Introduction
Diabetes mellitus (DM) is one of the most prevalent chronic conditions worldwide [1]. 
According to the WHO [2], we are currently experiencing a global diabetes epidemic with 
DM affecting 422 million adult individuals worldwide in 2014, compared to 108 million 
in 1980 and projected to be 7th leading cause of death by 2030. In the U.S. alone, the 
estimated total costs of diagnosed diabetes increased by 41% in a five year period, from 
$174 billion in 2007 to an estimated $245 billion in 2012 [3]. In the UK the cost of 
diabetes to the NHS is around 10% of the NHS budget for England and Wales [4]. 
Similarly, DM absorbs around 8% of total public health expenditures in Spain with an 
estimated €5.1 billion for direct costs and €1.5 billion for diabetes-related complications
[5].
The medical literature consistently finds that uncontrolled diabetes or poor glycaemic 
control resulting in higher levels of blood sugar is a prevailing condition concerning 
around 50% of diabetic patients [6, 7]. Glycaemic control is a major step in managing 
DM and is often driven by the interaction of genetic endowment, risk factors (e.g. whether 
and to what extent patients follow recommended diet and exercise regimens); therapeutic 
inertia or resistance to intensify medication; and poor treatment adherence [8, 9].
Uncontrolled diabetes has potentially severe consequences on patients’ health and well-
being exposing individuals to higher risks of life-threatening comorbidities such as heart 
disease and stroke as well as vision problems, kidney and nerves damages [10].
From an economic perspective, a related problem may be the additional health care 
utilisation caused by uncontrolled diabetes. Individuals with uncontrolled diabetes may 
potentially use more health care resources resulting in extra utilisation and added costs 
for the health system as well as further loss in productivity due to work absence, work 
limitations, lower earnings and early mortality [11-13]. Furthermore, whereas 
uncontrolled diabetes is a widespread phenomenon, robust evidence of its effects on 
health care utilisation is very limited, especially among European countries.
The economic literature has traditionally focused on the effects of diabetes on the labour 
market [14-18] and quality of life [19], yet it has so far overlooked its impact on health 
care utilisation. Similarly, previous medical evidence on the relationship between poor 
glycaemic control and health care use is often based on selected samples, mostly from 



































































instance, Wagner et al. [20] employ U.S. insurance claims data of patients with diabetes 
from a large Health Maintenance Organization (HMO) in the state of Washington 
between 1992-1997 to analyse the association between improved glycaemic control,
health care utilisation and costs. They employ linear and log-linear regression models and 
find that sustained reduction of HbA1c (glycated haemoglobin, a clinical measure of 
blood sugar) levels is correlated with lower utilisation and cost savings. Gilmer et al. [21] 
combine claims and survey data of diabetic patients in Minnesota with generalised linear 
models (GLM) and find that coronary heart disease (CHD), hypertension and depression 
are stronger predictors of health care costs than high baseline HbA1c levels. Oglesby et 
al. [22] use similar methods and data from the U.S. Health Core Managed Care Database
between 1998-2003 and observe that direct medical costs driven by type 2 diabetes were 
between 16% to 20% lower for individuals with good glycaemic control (HbA1c ≤ 7%).1
Recent evidence from Catalonia (Spain) based on primary care cross-sectional data 
focuses on costs and highlights that, among other findings, patients with poor glycaemic 
control had higher average costs (with increases of around 16%)  compared with patients 
with good control [24]. 2
In earlier studies, selected samples limit the generalisability of the results while standard 
linear models do not account for potentially relevant issues such as unobserved 
heterogeneity and selection which may affect the estimates of the effects of uncontrolled 
DM. A more accurate assessment of the health care consequences of uncontrolled 
diabetes will help enhance the evidence base for physicians to better plan treatments and 
for policy-makers to develop cost-effective interventions to increase adherence rates and 
reduce excess utilisation leading to resource inefficiencies. 
Accordingly, the main objective of this paper is to more accurately identify and quantify 
changes in healthcare utilisation driven by uncontrolled diabetes. To this aim, we made 
1 Similarly, Menzin et al. [23] focus on a subsample of managed-care diabetic patients from Massachusetts 
covering a 5-year period (2002-2006) and employ logit and GLM models. They notice that diabetes-related 
hospitalisations were significantly higher among patients with uncontrolled diabetes.
2 For a broader overview on the relationship between diabetes and its related costs, see the United Kingdom 
Prospective Diabetes Study UKPDS Outcomes Model; the Economic and Health Outcomes Model of Type 
2 Diabetes Mellitus (ECHO-T2DM); the Michigan Model for Diabetes (MMD); Cardiff Diabetes Model;
the School of Public Health Research (SPHR) Diabetes Prevention Model and the Modelling Integrated 
Care for Diabetes based on Observational data (MICADO) model [25-30]. Although they do not 
specifically focus on uncontrolled diabetes, these are comprehensive models capable of simulating the 
progression of diabetes under different scenarios, including diabetes-related complications and estimating 



































































use of rich longitudinal data from the province of Barcelona, Spain, and measured
uncontrolled diabetes using a biomarker, glycated haemoglobin (HbA1c). We focused on 
the effects of uncontrolled diabetes on primary and secondary care and exploited the 
longitudinal nature of the data by estimating panel count data models. These models 
accounted for unobserved heterogeneity, selection, previous utilisation and hence provide 
new evidence on the relationship between uncontrolled diabetes and health care use.  
2. Methods
2.1 Data 
We employed individual-level longitudinal data drawn from administrative records of 
patients from Catalonia, Spain, followed over seven consecutive years (2004-2010). More 
specifically, these data were drawn from 6 primary care centres and 2 hospitals in the 
municipality of Badalona (north-east of Barcelona), serving a population of around 
104,000 individuals. Since Spain has a national health care system which provides 
universal coverage, data from these health care centres are also representative of the way 
the health system operates in the whole country. Furthermore, within this system,
provision of health services is organised at regional level and free of charge at the point 
of delivery with the exception of pharmaceuticals which require some form of co-
payment.3
Our data included a rich set of information about patients’ use of health care resources,
including our three main outcomes of interest i.e. number of GP visits, specialist care and 
hospital length of stay.4 Our data also encompassed information on clinical measurements 
of height and weight (used to build an individual’s body mass index, BMI); patient’s 
chronic and diagnosed health conditions (classified according to the International 
Classification of Primary Care codes, second edition, ICPC-2); dates of hospital 
admission and discharge; type of healthcare professional(s) contacted; and the main 
reason for their visit. Moreover, the dataset included individual level socio-demographic 
3 Only individuals in employment would face a 40% co-payment for prescribed medicines, whereas 
pensioners would be completely exempted. Patients with chronic conditions would have a reduced co-
payment of 10% and civil servants would only pay 30% of the market price regardless of their employment 
status.
4 We focused on utilisation as it constitutes the largest component of diabetes-related medical costs. 
Furthermore, Mata-Cases et al. [24] using data from Catalonia report that hospital care, medications and 



































































characteristics such as age, gender, marital status, immigration (Spanish or EU national 
versus non-EU national) and employment status (active vs retired), place of birth and 
residence and health-behaviours (tobacco and alcohol use). 
Given the purpose of this study, we focused on a sub-sample of individuals with 
diagnosed type 2 diabetes mellitus (DM), aged 16 years or over, who had at least one 
contact with the aforementioned hospitals and primary health care centres between 1 
January 2004 and 31 December 2010.5 Individuals transferred or moved to other health 
centres and patients from other areas were excluded from our analysis. Patients with 
diabetes were identified via the corresponding ICPC-2 code or alternatively through a
mean HbA1 level ≥ 6.5% (≥ 48 mmol/mol) [31] based on a glycated haemoglobin 
(HbA1c) test reported by physicians. This test is routinely used by clinicians to diagnose 
and monitor diabetes and should provide an accurate measure of glucose concentration 
up until the previous 8 weeks [31-33].
Our main variable of interest was uncontrolled type 2 DM, which we defined using a 
binary variable. We assumed that patients with diabetes were not adequately controlling 
their condition when their within year mean HbA1c level was equal or above 7.5%. We 
chose this threshold as it was used by physicians in the area of Badalona during the period 
2004-2010 to identify poor control among patients in our data. However, since there is 
no universal consensus within the medical literature about the HbA1c thresholds which 
identify uncontrolled diabetes, we also estimated our models using a slightly lower value 
of blood sugar concentration (7%) [33].6 As in the majority of studies using administrative 
data, information on HbA1c levels was not available for the entire sample of patients with 
diabetes. In our data there might be patients with repeated measurements within a year; 
other patients diagnosed as diabetics via ICPC-2 codes without any actual HbA1c 
measurement or others missing HbA1c measurements just for selected years. Given our 
definition of uncontrolled DM, we restricted our sample to individuals with at least one 
within year mean HbA1c value. Following this criteria, we obtained a sample of 29,363 
patients with type 2 DM.7
5 The sample may include patients with diabetes with zero utilisation (no GP visits or hospital admissions) 
in some of these years. These might be patients who had some positive use only in selected years. Note that 
we dropped all individuals with type 1 diabetes.
6 Results obtained using a lower threshold appeared to be very similar and are available upon request. 
7  It might be argued that excluding patients without positive within year HbA1c means could potentially 




































































We focused on the effects of uncontrolled diabetes on three main outcomes: the number 
of GP and specialist visits and hospital length of stay. Given that these are non-negative 
integer outcomes and to exploit the panel element of our data, we estimated panel count 
data models that account for individual-level unobserved heterogeneity. 
More specifically, we present estimates on the effects of uncontrolled diabetes on the 
number of GP visits obtained using negative binomial (NB) models with random effects 
(RE).8 This is a flexible specification which is often used to model health care utilisation 
in the economics literature as it goes beyond standard Poisson models allowing for 
overdispersion together with unobservables [35, 36].9
We modelled the number of specialist visits and hospital length of stay using hurdle (two-
part) models. The previous literature points out that the decision to contact a physician 
and the one concerning the amount of visits may be the result of two distinctive decision-
making processes [37-39]. Further, these decisions might depend on both the individual 
and the physician, or more generally the heath care provider, and the complexity of this 
process may be exacerbated by repeated decisions in the presence of longitudinal data.10
This might also have been the case in our data when we analysed specialist visits (i.e. the 
decision to see a specialist vs. the number of visits) and hospital length of stay (i.e. the 
decision to walk into a hospital vs. length of stay) for patients with type 2 diabetes. 
Accordingly, we employed two-part or hurdle specifications to account for these two 
separate decisions. In our case, the first part of the hurdle was a probit model that 
distinguishes between users and non-users while the second part estimated the intensity 
of use (conditional on positive use) through a NB2 model with RE. This approach was
also motivated by the relatively high frequency of zeros (non-use) for these two outcomes. 
All these models exploited variations in utilisation between the years 2004-2010 and 
accounted for a number of individual observable characteristics, individual-level 
individuals also appeared to be overall healthier than the remaining patients with diabetes with full HbA1c 
information and ultimately this may contribute to their lower levels of health care consumption.
8 More specifically, we estimated the so-called negative binomial 2 (NB2), a model where the conditional 
variance function is quadratic in the mean [34]. 
9 We have also estimated Poisson specifications. Results were similar to the ones presented here and are 
available upon request.
10 In the Spanish National Health Service, GPs exert a gatekeeper role and refer patients to specialist doctors 



































































unobserved heterogeneity, years and geographical area (local health authorities) fixed 
effects. Our basic specification was:
 =   ! " + #$ +  + % + & + '     (i=1,…,N;t=1,…,T;j=1,…,J)         (1) 
where ( was  health care utilisation, that is alternatively the number of GP visits, 
specialist visits or hospital length of stay of individual i, in (health authority) area j at time 
t.  ! was  our main variable of interest as it defined uncontrolled diabetes via the 
biomarker HbA1c. Following the medical literature in our basic specification we defined 
uncontrolled diabetes in the presence of within year average values of HbA1c ≥7.5%.
This variable was lagged one period to address endogeneity and exploit the timing of 
uncontrolled DM to more precisely identify the effects of uncontrolled diabetes on our 
measures of utilisation.11 We also estimated alternative specifications of uncontrolled 
diabetes using increasing levels of HbA1c, i.e. 7.5%≤HbA1c<8.5%; 8.5%≤HbA1c<9.5; 
and HbA1c≥9.5%. We did this to explore the potential presence of a gradient in health 
care utilisation driven by the severity of an individual’s condition. # was a vector that 
included socio-demographic individual-level observable variables as well as clinically 
assessed health conditions. These included age (a third order polynomial for age, i.e. age, 
age squared and cubic age, to capture non-linear age effects); labour market status (being 
active in the labour market contrasted against being inactive); immigration status (being 
a non-EU immigrant versus a Spanish or EU citizen as a baseline); marital status (living 
alone versus married/with a partner); health-behaviours (alcohol consumption, smoking 
status and objectively measured BMI); a series of diabetes-unrelated chronic health 
conditions (i.e. asthma; chronic obstructive pulmonary disease, COPD; dementia; 
psychosis; clinical depression; and cancer); as well as diabetes-related health conditions 
(i.e. cardiovascular disease, cerebrovascular disease, neuropathy and heart failure). All 
models also included time dummies  which accounted for time trends while %
identified primary health authority areas (defined at geographical level) fixed effects. &
                                                          
11 We also explored the presence of simultaneity in our data between uncontrolled diabetes and health care 
utilisation as well as the use of the lagged value of our biomarker as an instrument via a two stage least 
squares (2SLS) estimation strategy [40]. Tests performed by following Reed [40] suggested, as expected, 
the presence of statistically significant (yet quantitatively small) simultaneity as well as statistically 
significant serial correlation between contemporaneous and lagged measures of uncontrolled DM. 2SLS 
estimates performed using pooled and panel linear models as well as specifications accounting for binary 
endogenous regressors appeared to suggest larger effects of uncontrolled diabetes compared to non-
instrumented models. Since none of these 2SLS specifications closely reflected our preferred panel count 
data models and implausibly larger effects, we preferred to report findings from NB2 RE specifications, 



































































represented individual-level time-invariant unobserved heterogeneity and  was the 
idiosyncratic error term.  
Importantly, we also examined whether and to what extent the effects of poor glycaemic 
control on utilisation were mediated by the number of patients’ diabetes-related health 
conditions. To purge our estimates from such influences, we run our models on a sample 
of “healthy users”, i.e. patients with diabetes without the aforementioned diabetes-related 
conditions. This identified both the relative contribution of diabetes complications and 
the “pure” or net effect of UD on health care utilisation. 
Conditionally correlated random effects  
To allow for correlation between observables and individual unobserved heterogeneity, 
we parameterised the individual effect   as a function of the within individual means of 
the exogenous regressors [41-43].12 This simply translated into including among our 
regressors the within mean of the time-varying exogenous (continuous) variables, i.e. ".
In our case, this included the average over the sample period of the variables defining 
age, BMI and the annual average value of the biomarker. 
Robustness checks 
In order to separately account for individual-level unobserved heterogeneity and the 
effects of previous period (t-1) health care utilisation on current consumption, we also 
estimated dynamic NB2 models with RE. This approach extended the previous 
conditionally correlated random effects model already augmented by a Mundlak 
correction by including among our regressors values of the dependent variables lagged 
one period, #$%&, as well as initial conditions in the parameterisation of the individual 
effect [44]. That is, we also included among our regressors initial (wave 1) values of our 
dependent variable, i.e. #,$,'. Note that these estimates were performed on a balanced 
panel sample where patients observed during seven consecutive years (2004-2010) to 
12 For a more recent discussion on the use of the conditionally correlated (CCR) random effects models 
applied to count data models, including negative binomial models, see [43]. Note that since the random 
effect in negative binomial models applies to the distribution of the dispersion parameter, in this case, this



































































allow accounting for initial conditions and values of the lagged dependent variables. As 
such, these dynamic models were estimated on a smaller sample of individuals. 
Finally, since the medical literature often finds higher percentages of poor control and 
non-adherence among males and this may have an impact on subsequent health care 
utilisation, we estimated separate models by gender. 
3. Results
Descriptive statistics
The prevalence of DM in the full dataset of 104,000 patients (including individuals with 
and without diabetes) increased from 6.4% in 2004 to 9.3% in 2010. As expected, the 
prevalence was substantially higher for those aged 65 years or over (21.1% in 2004 versus 
25.3% in 2010). Our sample of patients diagnosed with type 2 diabetes, defined using 
both physicians’ disease classification codes and blood tests with at least one HbA1c 
measurement, reduced to 29,363 observations over the period 2004-2010. 
(Table 1 around here) 
Table 1 reports descriptive statistics for both the sample of all patients with diabetes and 
the one that only included individuals with uncontrolled diabetes (HbA1c>=7.5%). Both 
samples were broken down by gender. Within our sample of individuals with diabetes, 
the mean number of GP visits per year were 15.46 (men) and 18.70 (women), while these 
reduced to 4.51 (men) and 4.83 (women) in the case of specialist visits and 0.58 (men) 
and 0.72 (women) for hospital length of stay. We also noted that this sample included
mainly older individuals with a mean age of 66.9 years and their mean HbA1c value was
7%. Importantly, our dataset showed that a significant number of individuals are not 
controlling adequately their condition despite the well-known potentially life-threatening 
health consequences caused by the diabetes-related complications: uncontrolled diabetes 
(HbA1c levels ≥ 7.5%) is 30.53% for men and 27.59% for women. For patients with 
uncontrolled diabetes health care consumption was higher, especially their primary care 
use: GP visits increased to 16.32 (men) and 20.18 (women), specialist visits to 4.68 (men) 
and 5.15 (women), while hospital length of stay grew only marginally to 0.63 (men) and 



































































systematically consume more health care compared to men. Patients of both genders with 
uncontrolled diabetes presented average HbA1c levels of 8.7%.13
Our three main outcome variables appeared to present a highly right-skewed distribution 
with a long tail indicating a very large consumption of resources by a small fraction of 
patients with diabetes.14 Another relevant feature of the dataset was the existence of zero 
visits during the years 2004-2010. This was negligible for GP visits (1.15%) but increased
to 20% for specialist visits and 89% for hospital length of stay.15 Hence, the existence of 
a zero mass problem in the data appeared to be of concern only in case of specialist visits 
and hospital length of stay. This ultimately justified our decision to examine such 
outcomes through a hurdle approach.
Main results 
We present separate estimates by gender on an unbalanced panel. All tables report 
average marginal effects.
(Table 2 around here) 
The first two columns of Table 2 show the estimates of our variable of interest, the lagged 
value of the biomarker detecting UD, on the number of GP visits for men and women.16
We found that for men, the effect of UD was positive and statistically significant with a 
quantitative effect of 0.48 GP visits, i.e. UD increased the average number of GP visits 
by around half a visit per year. This translated into an increase of almost 3% of the annual 
GP visits of men driven by poor glycaemic control. Although the effect of UD on GP 
visits for women also appeared to be positive, it was not statistically significant. 
13 Men with poor glycaemic control were slightly younger and more likely to be immigrants; in the labour 
market; to consume alcohol and tobacco smoke; and had a higher BMI than men who better control their 
condition. Men with uncontrolled diabetes presented higher percentages of depression, heart and 
cerebrovascular diseases. Women who did not control adequately their blood sugar levels appeared to be 
also somewhat younger; more likely to be in the labour market; and also showed increased percentages of 
alcohol and tobacco consumption and a higher BMI. This category of women also presented a higher 
incidence of depression, heart and cerebrovascular diseases. See Table A in the Appendix for further 
descriptive statistics broken down by time periods (2004, 2007, and 2010) for the main variables of interest. 
14 For instance, the variance of GP visits was 9 times greater than its mean. The same applies to specialist 
visits (6.5 times) and hospital stays (18 times). 
15 Once we conditioned on positive counts, the average number of specialist visits was 5.87 per year and 
the average length of stay was 5.19 days per year.
16 Note that we lost some observations (i.e. those of the initial year, 2004) when using the one-period lagged 



































































In columns (3) and (4) we report the effects of UD on specialist visits using a hurdle RE 
NB2 model. Again, estimates differed by gender as the quantitative effects were positive 
but only statistically significant for men. More specifically, we found that among male 
individuals with diabetes, the effect of having HbA1c≥7.5% in the previous period led to 
an increase of specialist visits of 0.25 (at 5% significance level) conditional to positive 
visits. This corresponded to a percentage increase of 5.3 in the number of annual specialist 
visits. Finally, the last two columns of Table 2 present the effects of UD on hospital length 
of stay using the same hurdle approach. These models presented a reduced number of 
observations as a consequence of the larger number of zeros in the data for these 
outcomes. Interestingly, we found again marked gender-related differences since UD was 
solely associated with an increase in the number of days in hospital among male patients. 
Specifically, the results indicate that one-year lagged uncontrolled DM led to a 
statistically significant increase of 0.78 additional days in hospital, conditional to positive 
stays (i.e. admission into an hospital). This corresponded to an increase of 15.1% in the 
annual length of stay.17
(Table 3 around here) 
Table 3 presents estimates from RE NB2 as well as hurdle RE NB2 for a sub-sample of 
healthy-users. Interestingly, these estimates appeared to substantially confirm the ones 
presented in Table 2. Among men, we found statistically significant effects of UD on both 
GP and specialist visits. These effects were quantitatively larger if compared to the results 
obtained from the more general sample of individuals with diabetes in Table 2 with 
increases of 0.56 (3.4%) and 0.28 (6.1%) of annual GP and specialist visits, respectively.
This implied that for men, increases in health care consumption may be mainly driven by 
UD and not necessarily its related complications. We also found a weakly significant 
effect of UD on hospital length of stay, conditional on admission. As for the previous 
models in Table 2, we did not identify any effects for women that were statistically 
different from zero. 
(Table 4 around here) 
17 We have also estimated the same models on a pooled sample of men and women and found slightly lower
quantitative effects for men. This is not surprising as this should be a direct result of the sample pooling 



































































Conversely, since reduced glycaemic control increases the risk of diabetes-related 
complications and this may in turn influence health care use, Table 4 examines potential 
non-linearities in the effects of UD by defining increasing levels of this condition: low 
(7.5%≤HbA1c<8.5%); moderate (8.5%≤HbA1c<9.5) and high (HbA1c>=9.5%) UD. Our 
estimates showed that the raise in GP visits among men with diabetes were mainly 
concentrated among those with low and moderate levels of UD with increases of 0.4 and 
nearly 0.7 GP visits respectively. Among men, we also found statistically significant 
effects of low and high UD on specialist visits with the largest effect observed for 
individuals with the poorest control (high UD). Our estimates showed that having low 
and high levels of UD in the previous year led to annual increases of 0.26 and 0.46 
specialist visits respectively, conditional on having a specialist visit. These corresponded
to average increases of around 4.4% and 7.8%. Men also presented a positive, large and 
highly statistically significant effect of low UD and only a weakly significant effect 
(although also large) of high UD on hospital length of stay. The effect of low UD on 
utilisation implied an additional 1.1 days in hospital, representing a mean annual increase 
in the length of stay, conditional on having a hospital admission, of 21%. It should be 
noted that for women, none of the effects related to UD were statistically significant. 
(Table 5 around here) 
Table 5 provides results from dynamic RE NB2 and hurdle models on a balanced sample. 
Statistically significant persistence of health care consumption appeared to be present for 
both genders and for both GP and specialist visits. However, this did not appear to play a 
major role among the determinants of hospital length of stay for men and also presented
a negative effect on consumption for women.18
18 This is expected and might be related to the different nature and frequency of health care consumption 
identified by the three outcomes considered: hospital admission is a much rarer event if compared to GP
and specialist visits. Interestingly, in this case we found statistically significant effects of UD on GP visits 
among women and only on specialist visits amongst men, although only significant at 10%. In any case, 
we should be cautious in the interpretation of the effects of past heath care consumption on current use 
because these might be also partly driven by previous (further back in time) levels of UD. Also, given the 
substantial drop in the number of observations when using a balanced sample, we should be careful in 
comparing these estimates with our main results. Furthermore, we also run the same dynamic specifications 




































































4. Discussion and Conclusion
Evidence on the effects of uncontrolled diabetes on health care utilisation is sparse, 
particularly among European countries. Results from previous US medical studies are 
mixed, often based on limited data and standard linear models as well as self-reported 
information that may be plagued by reporting bias. We employed detailed longitudinal 
data on a large population of adult individuals with diabetes, and used a clinically assessed 
biomarker together with panel count data models to estimate the effects of uncontrolled 
diabetes on GP and specialist visits as well as hospital length of stay. 
Our administrative data drawn from the municipality of Badalona presented estimated 
mean HbA1c value  of 7% close to the figure for the whole region of Catalonia [45] and 
diabetes prevalence rates similar to those at national level in Spain for the same years [8, 
46]. Consistent with evidence found in other developed countries, our analysis confirmed
that a large fraction of patients with diabetes (between 27 to 30%) appeared to poorly 
control their condition. This led to an excess use of GP (3%), specialist visits (5.3%) and
increases in the annual hospital length of stay (15%) for men. The latter figure may imply 
that, although hospitalisation is a relatively rare event for patients with diabetes, 
uncontrolled diabetes increases the length of hospital stay, therefore imposing additional 
costs on the health system. Importantly, models for male “healthy-users” (which exclude 
diabetes-related complications) presented quantitatively larger effects of uncontrolled 
diabetes on health care utilisation in both primary and secondary care. This confirmed
that among men in our sample, variations in utilisation were primarily influenced by 
uncontrolled diabetes.  
Our data indicated that although women with diagnosed type 2 DM appeared to 
consistently consume more health care compared to men, as confirmed by the previous 
medical literature [47, 48], we found that their higher consumption did not seem to be 
influenced by uncontrolled diabetes. As such, our findings suggested the presence of 
gender-related heterogeneity in health care consumption for similar levels of uncontrolled 
DM. However, further research and data with a wider set of socioeconomic variables 
might be needed to more precisely establish the reasons behind this difference.   
Furthermore, although we did not identify clear-cut gradients in the effects of different 
levels of uncontrolled diabetes on utilisation, we found heterogeneous effects for men. 



































































those with low and moderate levels of uncontrolled diabetes. This could suggest that 
individuals with high levels of uncontrolled DM might be less aware of their condition or 
its consequences and this may in turn influence their decision not to follow up with 
appropriate health treatments and visits. In addition, we found an increase in the hospital 
length of stay among male patients with low levels of uncontrolled diabetes. Yet, the 
annual increase in specialist visits, conditional to a positive number of visits, concerned
patients having both low and high levels of inadequate control. Given the need to a GP 
referral to access specialist care, this finding should be interpreted somehow differently 
and, in any case, does not solely depend on a patient’s behaviour.
As usual, this study may have some limitations. First, our data did not include some 
potentially relevant supply side factors such as physicians’ density that might affect the 
frequency of visits [36]. However, it can be argued that some of these (time-invariant) 
factors might be absorbed and proxied by our local health area fixed effects. Secondly, 
we were not able to include information on the duration of diabetes. This is mainly 
because dates of first diagnosis were not systematically available for all individuals in our 
data. In addition, we excluded from our analysis individuals transferred or moved to other 
health care centres. Yet, since movements across centres are relatively rare events, this 
exclusion is unlikely to have a major impact on our main results. Finally, it should be kept 
in mind that whereas our econometric methods were capable of estimating the statistical 
association between uncontrolled diabetes and health care utilisation over time, they did
not identify causal effects. They improved on previous analyses by accounting for 
important issues in modelling the uncontrolled DM-health care use relationship such as 
selection, unobserved heterogeneity and dynamics.  
Overall, our results suggested the presence of marked gender-related differences as well 
as potential heterogeneous behaviours in health care consumption depending on different 
levels of uncontrolled diabetes among men. These findings may have important 
implications for physicians and policy makers potentially suggesting the need for 
different diabetes management plans depending on gender and levels of glycaemic 
control. Since diabetes is the most widespread chronic condition worldwide, improving 
blood sugar control would not just be beneficial to patients’ wellbeing but would also 
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Table 1: Descriptive statistics: Years 2004-2010 
Diabetics Diabetics with HbA1c ≥ 
7.5%
Men N Women N Men N Women N
GP Visits 15.46 14515 18.70 14848 16.32 4432 20.18 4096
Specialist 
visits
4.51 14515 4.83 14848 4.68 4432 5.15 4096
Hospital stays 0.58 14515 0.72 14848 0.63 4432 0.77 4096
HbA1c level 7.08 14515 7.00 14848 8.69 4432 8.68 4096
Uncontrolled 
DM *
30.53 14515 27.59 14848 - 4432 - 4096
Age 65.28 14515 68.54 14848 63.54 4432 67.66 4096
Immigrant 1.41 14515 1.68 14848 2.73 4432 2.37 4096
Active 28.46 14493 17.17 14802 34.46 4422 18.45 4075
Living alone 90.83 14515 83.99 14848 90.55 4432 83.76 4096
Alcohol 5.28 14515 0.63 14848 5.80 4432 0.71 4096
Tobacco 29.82 14515 6.97 14848 33.73 4432 8.64 4096
BMI 29.26 14319 31.23 14619 29.31 4352 31.73 4017
Asthma 1.80 14515 7.00 14848 1.65 4432 6.81 4096
CPOD 9.71 14515 2.23 14848 9.05 4432 2.54 4096
Dementia 1.30 14515 2.69 14848 1.65 4432 2.91 4096
Psychosis 1.03 14515 1.04 14848 1.08 4432 0.66 4096
Depression 9.39 14515 25.74 14848 10.24 4432 28.32 4096
Malignant 
neoplasm
7.22 14515 6.81 14848 5.75 4432 6.91 4096
Hypertension 55.53 14515 70.35 14848 49.99 4432 68.04 4096
Dyslipidemia 53.75 14515 57.89 14848 50.10 4432 57.84 4096
Heart 
Diseases
16.18 14515 8.53 14848 17.89 4432 9.38 4096
Cerebrovasc.
D.
5.95 14515 1.85 14848 6.34 4432 3.03 4096
Heart failure 12.18 14515 12.72 14848 11.17 4432 12.06 4096
Neuropathy 0.87 14515 1.27 14848 0.81 4432 1.20 4096



































































Table 2: The effects of uncontrolled diabetes on health care utilisation 
Hurdle Models
(1) (2) (3) (4) (5) (6)









UD (t-1) 0.483** 0.241 0.249** 0.155 0.777** 0.111
(0.192) (0.230) (0.119) (0.127) (0.316) (0.369)
N 11763 12147 9235 9924 1394 1574
UD (t-1) stands for uncontrolled type 2 diabetes as measured by HbA1c>=7.5% lagged one period. Table 
displays average marginal effects (AME) for static RE NB2 model augmented by a Mundlak specification 
(unbalanced sample). All models control for the full set of covariates. Standard errors in parentheses. * p <
0.10, ** p < 0.05, *** p < 0.01.  
Table 3: The effects of uncontrolled diabetes on health care utilisation – healthy 
users 
Hurdle Models
(1) (2) (3) (4) (5) (6)









UD (t-1) 0.560** 0.097 0.286** 0.216 0.718* 0.066
(0.219) (0.248) (0.139) (0.141) (0.368) (0.423)
N 8179 9466 6180 7633 832 1125
UD (t-1) stands for uncontrolled type 2 diabetes as measured by HbA1c>=7.5% lagged one period. Table 
displays average marginal effects (AME) for static RE NB2 model augmented by a Mundlak specification 
(unbalanced sample). All models control for the full set of covariates. Standard errors in parentheses. * p <



































































Table 4: The effects of uncontrolled diabetes on health care utilisation - HbA1c 
levels 
Hurdle Models
(1) (2) (3) (4) (5) (6)









UD1 [7.5, <8.5%] 
(t-1)
0.412** 0.310 0.261** 0.122 1.099*** 0.058
(0.210) (0.248) (0.130) (0.137) (0.353) (0.401)
UD2 [8.5, <9.5%] 
(t-1)
0.669** 0.343 0.125 0.245 -0.014 0.393
(0.303) (0.360) (0.187) (0.195) (0.468) (0.524)
UD3 [>=9.5%] (t-1) 0.582 -0.504 0.459** 0.206 1.027* -0.335
(0.384) (0.449) (0.232) (0.244) (0.553) (0.680)
N 11763 12147 9235 9924 1394 1574
UD1,2,3 (t-1) stands for the uncontrolled type 2 diabetes defined within the corresponding HbA1c interval 
lagged one period. All models present average marginal effects (AME) for static RE NB2 models 
augmented by a Mundlak specification (unbalanced panel). All models control for the full set of covariates. 
Standard errors in parentheses. * p < 0.10, ** p < 0.05, *** p < 0.01 
Table 5: The effects of uncontrolled diabetes on health care utilisation – dynamic 
models  
Hurdle Models
(1) (2) (3) (4) (5) (6)









UD (t-1) 0.431 0.871*** 0.380* 0.001 -0.131 -0.523
(0.292) (0.310) (0.198) (0.183) (0.478) (0.495)
GP visits (t-1) 0.186*** 0.106*** - - - -
(0.0137) (0.0106)
Spec. visits (t-
1)          
- - 0.118*** 










N 3738 4704 3122 4094 468 602
UD (t-1) stands for uncontrolled type 2 diabetes as measured by HbA1c>=7.5% lagged one period; GP 
visits (t-1) stands for the number of GP visits lagged one period; Spec. visits (t-1) for number of specialist 
visits lagged one period; Hosp. Stays (t-1) for the length of hospital stays lagged one period. Table displays 
average marginal effects (AME) for dynamic RE NB2 model augmented by initial conditions and a 
Mundlak specification (balanced sample). All models control for the full set of covariates. Standard errors 




































































Table A: Descriptive statistics for selected years 
A) Individuals with diabetes
Men Women
2004 2007 2010 2004 2007 2010
GP Visits 14.92 15.53 15.72 17.87 18.80 19.02
Specialist visits 3.35 4.27 5.09 3.74 4.77 5.31
Hospital stays 0.48 0.60 0.68 0.61 0.83 0.79
HbA1c level 7.14 6.91 7.34 7.15 6.78 7.29
Uncontrolled DM * 33.00 26.93 35.79 30.74 23.26 32.30
* Uncontrolled DM is defined for HbA1c values ≥ 7.5%.
B) Individuals with uncontrolled diabetes (HbA1c ≥ 7.5%)
Men Women
2004 2007 2010 2004 2007 2010
GP Visits 15.96 16.07 16.65 18.36 21.05 20.41
Specialist visits 3.95 4.14 5.20 4.10 5.23 5.44
Hospital stays 0.68 0.38 0.79 0.58 1.25 0.83
HbA1c level 8.61 8.76 8.64 8.70 8.65 8.68
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